Trials / Recruiting
RecruitingNCT04541381
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 860 (estimated)
- Sponsor
- University of Chicago · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Doctors leading this study hope to find out if giving study participants' genetic information to cancer care providers will help personalize chemotherapy dosing decisions and decrease common chemotherapy side effects. Doctors leading the study will collect genetic information from study participants using pharmacogenomics/genotyping. Pharmacogenomics is the study of how the differences in our genes can affect our unique response to medications. This is a randomized study, which means that participants in this study will be randomly assigned (as if "by flip of a coin") to one of two different groups: a "pharmacogenomics group" or "control group".
Conditions
- Gastrointestinal Cancer
- Head and Neck Cancer
- Dihydropyrimidine Dehydrogenase Deficiency
- UGT1A1 Gene Mutation
- Breast Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Availability of clinical decision support based on pharmacogenomic results. | Availability of clinical decision support based on pharmacogenomic results. These results are designed to provide specific dosing information based on the participant's unique genetics/genomics. |
Timeline
- Start date
- 2022-02-07
- Primary completion
- 2027-10-01
- Completion
- 2028-03-31
- First posted
- 2020-09-09
- Last updated
- 2026-03-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04541381. Inclusion in this directory is not an endorsement.